In this issue:
Cancer risk for BRCA1 and BRCA2 mutation carriers
Adjuvant capecitabine improves survival in HER2– residual invasive disease
Substantial treatment-related toxicities in early-stage invasive disease
Estimating the risks of modern RT regimens
Post-chemotherapy rehabilitation: long-term QoL effects
Rapid, deep ovarian reserve alteration after chemotherapy
HER2 status predicts for upfront AI benefit
Optimal duration of adjuvant chemotherapy in high-risk N– disease
TDM-1 improves OS in previously treated HER2+ disease
Adding gemcitabine to an anthracycline/ taxane base: no advantage
Please login below to download this issue (PDF)